FibroGen Inc (FGEN)

$ 18.57
-0.24 (-1.28%)
Neutral
Symbol FGEN
Price $ 18.57
Beta 1.684
Volume Avg. 1.47M
Market Cap 1.70B
Shares () -
52 Week Range 18.12-57.209
1y Target Est -
DCF Unlevered -
DCF Levered -
ROE -43.82% Strong Sell
ROA -22.89% Sell
Operating Margin -
Debt / Equity 91.29% Buy
P/E -
P/B 4.01 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm

ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against FibroG...

LOS ANGELES, April 9, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of FibroGen, Inc. ("FibroGen" or "the Company") (NASDAQ: FGEN) for violati... ...

PRNewsWire
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen (FGEN) Investors with Losses to Contact Its Attorneys Now, Company Admits to Manipulating Data for Anemia Drug

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen (FGEN) Investors with Losses to Contact...

San Francisco, California--(Newsfile Corp. - April 9, 2021) - Hagens Berman urges FibroGen, Inc. (NASDAQ: FGEN) investors with significant losses to submit your losses now. The firm is investigating possible securities fraud and certain investors may... ...

Newsfile Corp
FIBROGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating FibroGen, Inc. on Behalf of FibroGen Stockholders and Encourages Investors to Contact the Firm

FIBROGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating FibroGen, Inc. on Behalf of FibroGen St...

NEW YORK--(BUSINESS WIRE)-- #FederalSecuritiesLaws--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against FibroGen, Inc. (NASDAQ: FGEN) on behalf of FibroGen stockholders. Our inve... ...

Business Wire
Berman Tabacco Investigates Potential Securities Law Violations By California-Based FibroGen Inc. (FGEN) In Connection with Roxadustat "Clarification"

Berman Tabacco Investigates Potential Securities Law Violations By California-Based FibroGen Inc. (F...

San Francisco, California--(Newsfile Corp. - April 8, 2021) - Berman Tabacco, a national law firm representing investors, is investigating potential securities law claims against FibroGen Inc. (NASDAQ: FGEN) ("FibroGen" or the "Company"). FibroGen is...

Newsfile Corp
FGEN Stock: Berger Montague Investigates Potential Securities Fraud Claims Against FibroGen, Inc. (FGEN) For Manipulating Drug Data

FGEN Stock: Berger Montague Investigates Potential Securities Fraud Claims Against FibroGen, Inc. (F...

Philadelphia, Pennsylvania--(Newsfile Corp. - April 8, 2021) - Berger Montague is investigating potential securities fraud claims against FibroGen, Inc. ("FibroGen" or the "Company") on behalf of investors who purchased FibroGen securities (NASDAQ: F...

Newsfile Corp
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen (FGEN) Investors with Losses to Contact Its Attorneys Now, Company Admits to Manipulating Data for Anemia Drug

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen (FGEN) Investors with Losses to Contact...

SAN FRANCISCO, April 8, 2021 /PRNewswire/ -- Hagens Berman urges FibroGen, Inc. (NASDAQ: FGEN) investors with significant losses to submit your losses now. The firm is investigating possible securities fraud and certain investors may have valuable cl... ...

PRNewsWire
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, I...

LOS ANGELES--(BUSINESS WIRE)---- $FGEN #FGEN--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc. ...

Business Wire
Ademi LLP Investigates Claims of Securities Fraud against FibroGen Inc.

Ademi LLP Investigates Claims of Securities Fraud against FibroGen Inc.

MILWAUKEE, April 8, 2021 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against FibroGen (NASDAQ: FGEN).  The investigation results from inaccurate statements Fibrogen may have made regarding its business operations and p... ...

PRNewsWire
FibroGen Investor Alert

FibroGen Investor Alert

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In FibroGen To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - April 7, 2021) -  Faruqi & Faruqi, LLP, a l... ...

Newsfile Corp
INVESTOR ALERT: Kirby McInerney LLP Announces an Investigation of Shareholder Claims Against FibroGen Inc.

INVESTOR ALERT: Kirby McInerney LLP Announces an Investigation of Shareholder Claims Against FibroGe...

NEW YORK--(BUSINESS WIRE)---- $FGEN--The law firm of Kirby McInerney LLP is investigating potential claims against FibroGen Inc. (“FibroGen” or the “Company”) (NASDAQ: FGEN). The investigation focuses on the Company and its officers' possible violati... ...

Business Wire

About


Mr. Enrique Conterno
Healthcare
Biotechnology
Nasdaq Global Select

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. The company is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase II trial for the treatment of Duchenne muscular dystrophy. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was incorporated in 1993 and is headquartered in San Francisco, California.